Author:QF Pharmaceutical Group
Posted Time:2026-07-14 17:52
From July 11 to 12, 2026, the 43rd National Pharmaceutical Industry Information Annual Conference was grandly held in Changping, Beijing. During the conference, the "2025 Top 100 Chinese Pharmaceutical Enterprises by Main Business Revenue" list was officially released. QF Pharmaceutical Group was honored to be included, ranking 66th, and was also awarded the "2026 Chinese Pharmaceutical Industry Enterprise with Investment Value Potential".
Themed "Exploring Life, Creating the Future Together", this year's annual conference focused on the deep integration of technological and industrial innovation. The Top 100 Industrial Enterprises List has long been regarded as the "bellwether of the pharmaceutical industry", based primarily the China Pharmaceutical Industry Statistical Annual Report. This official annual report systematically documents the current economic performance of China's pharmaceutical industry and is widely recognized as an authoritative benchmark for measuring the comprehensive strength of pharmaceutical companies.
QF Pharmaceutical Group has been included in the list for many consecutive years. Remaining on the Top 100 list this year and receiving the special award fully demonstrate the industry's strong recognition of Qingfeng's operational strength, innovation capability, and investment value.
The year 2025 marked a critical juncture between the conclusion of the "14th Five-Year Plan" concluded and the planning of the "15th Five-Year Plan". Against a backdrop of slowing domestic market growth, intensifying industry competition, deep adjustments in global supply chains, and rising uncertainties from geopolitical conflicts, China's pharmaceutical industry continued to move forward under mounting pressure while undergoing the difficult transition structural adjustment and the transformation of growth drivers. Pharmaceutical companies faced unprecedented and severe challenges.
In response to this rapidly changing industry landscape, QF Pharmaceutical Group actively aligned itself with the Healthy China Initiative, adhering to a dual-engine strategy of "innovation" and "internationalization". The company focused on four major therapeutic areas—oncology, anti-infection, digestive system, and central nervous system—while accelerating its innovation-driven transformation. Focused on addressing unmet global clinical needs, QF Pharmaceutical Group is committed to providing high-quality, affordable medicines and fulfilling its responsibilities expected of a Top 100 enterprise.
In 2025, the company achieved remarkable results: A total of 12 pharmaceutical formulations were approved for market launch throughout the year, including the Class 1 innovative drug Yisuda® (Suraxavir Marboxil Tablets)—the world's second polymerase inhibitor and the firsrt to be independently developed in China. As China's new-generation specific anti-influenza drug, Yisuda®Suraxavir Marboxil Tablets, with their single-dose regimen capable of rapidly clearing the virus, have broken the import monopoly and were included in the 2025 National Reimbursement Drug List (NRDL). Additionally, two domestic first-generic drugs were launched (Vancomycin Hydrochloride Oral Solution and Perampanel Oral Suspension). During the same period, the company obtained four clinical trial approvals for Class 1 innovative drugs (KR230109, KR23343, KR23335, and DN022150 100mg) and completed project initiations for five frontier targets.
On the internationalization front, QF Pharmaceutical Group signed agreements for nine products across 20 overseas markets in 2025, covering emerging markets such as ASEAN, the Gulf region, North Africa, South America, and Central and North America.
Remaining on the Top 100 list and being recognized as an Enterprise with High Investment Potential not only serve as authoritative recognition of QF Pharmaceutical Group's operational performance in 2025 but also provides a strong endorsement of its future growth potential. As China embarks on the first year of the 15th Five-Year Plan, and amid the rapid transformation of the pharmaceutical industry, QF Pharmaceutical Group will continue to make greater contributions to the high-quality development of China's pharmaceutical industry through sustained innovation sustained investment in innovation and a well-established industrial presence.
